|
|
Article: Amicus Therapeutics Appoints Chief Financial Officer.
- Article from:
- PR Newswire
- Article date:
- October 2, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CRANBURY, N.J., Oct. 2 /PRNewswire/ -- Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of a range of human genetic diseases, today announced the appointment of James E. Dentzer as Chief Financial Officer (CFO). Mr. Dentzer joins Amicus from Biogen Idec Inc., where he served as Vice President and Corporate Controller.
"Jim has outstanding experience in the pharmaceutical and consumer products industries," stated Donald J. Hayden, Jr., Executive Chairman and Interim President and CEO of Amicus. "He is a great addition to what is already an excellent management team at ...